Description: Catalyst Pharmaceutical Partners, Inc. operates as development-stage specialty pharmaceutical company. It focuses on the development and commercialization of novel prescription drugs targeting rare (orphan) neuromuscular and neurological diseases and disorders. The company's principal product includes Firdapse that is in Phase III clinical trial for the treatment of Lambert-Eaton Myasthenic Syndrome. It also develops CPP-115, a GABA aminotransferase inhibitor for the treatment of epilepsy and other selected central nervous disease indications; and CPP-109 for the treatment of Tourette Syndrome. Catalyst Pharmaceutical Partners, Inc. has strategic collaboration agreement with BioMarin. The company was founded in 2002 and is based in Coral Gables, Florida.
Home Page: www.catalystpharma.com
CPRX Technical Analysis
355 Alhambra Circle
Coral Gables,
FL
33134
United States
Phone:
305 420 3200
Officers
| Name | Title |
|---|---|
| Mr. Patrick J. McEnany | Co-Founder, Chairman, Pres & CEO |
| Ms. Alicia Grande C.M.A., CPA, CMA, CPA | Chief Accounting Officer, VP, Treasurer & CFO |
| Dr. Steven R. Miller Ph.D. | COO & Chief Scientific Officer |
| Dr. Gary Ingenito M.D., Ph.D. | Chief Medical & Regulatory Officer |
| Dr. Preethi Sundaram Ph.D. | Chief Strategy Officer |
| Ms. Mary Coleman | VP & Head of Investor Relations |
| Mr. Brian Elsbernd J.D. | Chief Compliance Officer & Chief Legal Officer |
| Mr. Pete Curry Sr. | VP of Sales |
| Mr. Jeffrey Del Carmen | Chief Commercial Officer |
| Mr. Philip B. Schwartz | Corp. Sec. |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 19.305 |
|---|---|
| Trailing PE: | 31.7 |
| Price-to-Book MRQ: | 6.4746 |
| Price-to-Sales TTM: | 9.1396 |
| IPO Date: | 2006-11-08 |
| Fiscal Year End: | December |
| Full Time Employees: | 76 |